ReviewHeart failure reviews2021
Therapeutic angiogenesis with exosomal microRNAs: an effectual approach for the treatment of myocardial ischemia.
Review in Heart failure reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Significance of Stem Cell-Derived Exosomes in Femoral Head Necrosis: A Systematic Review and Meta-Analysis of Preclinical Studies.Stem cell reviews and reports · 2026Pooled it
- Extracellular vesicles as bioactive nanotherapeutics: An emerging paradigm for regenerative medicine.Theranostics · 2022Pooled it
- Development of a potency assay for CD34Scientific reports · 2023Trial
- Circulating exosomal miRNA in acute coronary syndrome: mechanisms, clinical relevance and future directions.Frontiers in molecular biosciences · 2026Review
- The impact of natural and engineered extracellular vesicles on post-myocardial infarction angiogenesis.Stem cell research & therapy · 2025Review
- Cardiac Organoid Model Inspired Micro-Robot Smart Patch to Treat Myocardial Infarction.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Critical analysis of descriptive microRNA data in the translational research on cardioprotection and cardiac repair: lost in the complexity of bioinformatics.Basic research in cardiology · 2025Review
- Predicting microRNAs and their Target Genes Involved in Sepsis Pathogenesis by using Bioinformatics Methods.Current pharmaceutical design · 2025Article
- Exosome-Integrated Hydrogels for Bone Tissue Engineering.Gels (Basel, Switzerland) · 2024Review
- Article
- Enhancement of cardiac angiogenesis in a myocardial infarction rat model using selenium alone and in combination with PTXF: the role of Akt/HIF-1α signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- M2 macrophage-derived exosomes promote angiogenesis and improve cardiac function after myocardial infarction.Biology direct · 2024Article
- Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.Pharmacological reports : PR · 2024Review
- Extracellular vesicles from differentiated stem cells contain novel proangiogenic miRNAs and induce angiogenic responses at low doses.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- ALK1 Signaling in Human Cardiac Progenitor Cells Promotes a Pro-angiogenic Secretome.Journal of cellular signaling · 2024Article
- Research progress of exosomes from different sources in myocardial ischemia.Frontiers in cardiovascular medicine · 2024Review
- Review
- MicroRNA‑378: An important player in cardiovascular diseases (Review).Molecular medicine reports · 2023Review
- MiR-130a-3p regulates FUNDC1-mediated mitophagy by targeting GJA1 in myocardial ischemia/reperfusion injury.Cell death discovery · 2023Article
- Extracellular Non-Coding RNAs in Cardiovascular Diseases.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic angiogenesis presents a potential approach for treating ischemic heart diseases especially in patients who are not appropriate candidates for traditional approaches of revascularization. This approach acts through inducing the neovascularization or maturation of pre-existing collateral vessels into functional arteries to bypass the blocked arteries and restore perfusion to ischemic myocardium. Successful stimulation of local angiogenesis can be established by the cross talk between stem cells, endothelial cells, and cardiomyocytes, which is mainly mediated by paracrine communication accompanied by secreted exosomes. Exosomes are extracellular vesicles carrying a complex of signaling molecules, such as microRNAs (miRs) that can modulate the function of recipient cells. Such particles have been indicated to exert cardioprotective role through providing signaling cues for angiogenesis, an effect ascribed mainly to their miRs content. Exosomal miRs-mediated therapeutic angiogenesis has been under drastic preclinical and clinical studies. In the current review, it was aimed to summarize pro-angiogenic exosomal miRs released by various cell types mediating angiogenesis, including stem cells, endothelial cells, and cardiomyocytes, which appear to exert a therapeutic effect on the myocardial ischemia. In brief, secreted exosomal miRs including miR-210, miR-23a-3p, miR-424, let-7f, miR-30b, miR-30c, miR-126, miR-21, miR-132, miR-130a-3p, miR-214, miR-378, miR-126, miR-133, and let-7b-5p could protect against myocardial ischemia through inducing cardiac angiogenesis and vascular regeneration resulting in the increase blood flow to ischemic myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.